Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Charles River Laboratories International's average EPS without NRI Growth Rate was -7.60% per year.
During the past 3 years, the average EPS without NRI Growth Rate was -2.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 2.90% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 11.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Charles River Laboratories International was 22.00% per year. The lowest was -26.50% per year. And the median was 13.70% per year.
Charles River Laboratories International (NYSE:CRL) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Charles River Laboratories International 3-Year EPS without NRI Growth Rate Related Terms
CRL vs RVTY, ICLR, MEDP: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Charles River Laboratories International's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's 3-Year EPS without NRI Growth Rate falls into.
Charles River Laboratories International 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -2.60% mean?
Charles River Laboratories International (CRL) has a 3-Year EPS without NRI Growth Rate of -2.60% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Charles River Laboratories International and its competitors. According to the industry distribution chart, Charles River Laboratories International ranks #112 out of 161 companies in the Medical Diagnostics & Research industry, placing it in the top 69.6%.
Is Charles River Laboratories International's 3-Year EPS without NRI Growth Rate too high?
Charles River Laboratories International's current 3-Year EPS without NRI Growth Rate is -2.60%. Based on the distribution chart, Charles River Laboratories International ranks #112 out of 161 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Charles River Laboratories International has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's 3-Year EPS without NRI Growth Rate compare to RVTY and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #112 out of 161 companies for 3-Year EPS without NRI Growth Rate. This places Charles River Laboratories International in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 10.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 10.70, based on 161 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Charles River Laboratories International and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current 3-Year EPS without NRI Growth Rate is -2.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Significantly Overvalued. The stock's GF Value™ is $194.25, compared to a current price of $278.26 — trading 43.2% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -2.60%. Charles River Laboratories International's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current 3-Year EPS without NRI Growth Rate is -2.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of $278.26 is trading 43.2% above its estimated GF Value™ of $194.25.
GuruFocus considers Charles River Laboratories International to be Significantly Overvalued.
Key valuation signals for CRL:
3-Year EPS without NRI Growth Rate: -2.60%
GF Value™: $194.25 vs. price of $278.26 (43.2% above fair value)
No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
69GF Score
Get the complete analysis for CRL
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRL has been successfully added to your 
